When people have Alzheimer’s disease, their brains slowly accumulate abnormal clumps of two proteins: amyloid and tau. At ...

Neither drug improves clinical outcomes in patients with late onset AD, joining a long list of unsuccessful attempts to treat AD with anti-amyloid therapies. Discussion These therapies are based ...

There exists no ‘amyloid cabal’” in Alzheimer’s research, neurologist Dennis Selkoe writes in response to Charles Piller’s ...

Low-level light therapy, also called photobiomodulation (PBM), has emerged as a promising approach to Alzheimer's treatment, ...

With early diagnosis of Alzheimer's disease comes the possibility of treatment to not only help manage symptoms but also slow ...

Eli Lilly has chalked up another regulatory approval for its anti-amyloid therapy for Alzheimer's disease, Kisunla, in China – the world's second-largest pharma market. The National Medical ...

Each episode of this journey through a disease state contains both a physician guide and a downloadable/printable patient ...

Eisai and Biogen's Alzheimer's therapy Leqembi will be ... The US regulator has granted accelerated approval to anti-amyloid therapy Leqembi (lecanemab) with a fairly broad label to treat patients ...

Alzheimer’s disease (AD ... researchers have produced numerous AD drugs targeting amyloid beta only for them to fail in clinical trials. Scientists have only shifted focus more recently to developing ...

Histological examination shows amyloid ... CAA), [6] which is associated with activation of complement and microglia. Additionally, trials of anti-Aβ vaccination in patients with Alzheimer's ...

Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) are expected to face another delay in launching their new Alzheimer's drug ... decision that endorsed the anti-amyloid therapy. After declining ...